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LETTER TO THE EDITOR
Prognostic value of the S-phase fraction of breast cancer
Sir - The publication in the November issue of the British
Journal of Cancer of an article entitled 'Lack of prognostic
significance of DNA ploidy and S-phase fraction in breast
cancer', raises a number of questions, which the accompany-
ing editorial by W. Miller, while attempting to justify the
decision to publish the aforementioned article, does not ans-
wer. Most of the points I wish to discuss in my letter concern
the general field of prognostic factors and their application to
breast cancer treatment.
The authors critically reassess the results on DNA-ploidy
and SPF in the literature. Some of the criticisms, in partic-
ular concerning the use of multivariate analysis are justified.
But there are some discrepancies in the comparison of their
own results with those of previous studies. Thus, although
the Stanton paper clearly presents negative results - it suffices
to read its title - at the end of the discussion, they agree that
most authors have provided evidence showing that SPF is a
significant prognostic factor. Taking the comparison a little
further, they state that their own data are in general agree-
ment with the literature, since they at least observed a trend.
A statistical explanation (type II error) is even proposed. In
fact their conclusion is the same as that of a recent review on
the subject (O'Reilly & Richards, 1992), i.e. that SPF is a
significant prognostic factor, worth pursuing, but that DNA-
ploidy is not. This is certainly not the impression that the
reader would get from the title and the abstract.
How can we now improve our understanding of the value
of DNA flow cytometry in defining breast cancer prognosis?
Technical aspects can certainly be proposed. It is striking
that the data on 3H-thymidine labelling of surgical biopsies
of breast cancer seem to be more homogeneous (Meyer,
1986; Hery et al., 1987; Tubiana et al., 1989; Silvestrini et al.,
1989). The mitotic index has also been successfully used for
over 35 years, as part of histopathological grading (Bloom &
Richardson, 1957). Therefore, the proliferative activity of
breast cancers appears to be an important biological deter-
minant of outcome, but, from a methodological point of
view, the best way to measure it still remains an unresolved
question.
In a study, soon to be published, six experienced 'cytomet-
rists' were asked to classify some 400 DNA histograms of
breast cancers. The interesting conclusion of this work was
that the prognostic significance of DNA ploidy was maximal
for the histograms that were agreed on, whereas for those for
which opinions diverged, the outcome was similar to that of
the aneuploid group (Joensu et al., 1992). The major role of
subjective elements in the interpretation of DNA histograms
may be an important limitation of DNA flow cytometry, and
attempts to standardise this interpretation should be in-
stituted prior to its routine use in clinical practice.
In the excellent 'evaluation guidelines' for prognostic fac-
tors, the technical aspects were adequately dealt with
(McGuire, 1991), but the ever expanding field of prognostic
factors raises the general problem of their multiple intercor-
relations, potentially generating confusion for their practical
application. One of the aspects that is seldom tackled con-
cerns the search for an explanation of their association with
clinical outcome. Along these lines, it is indicative that the
results of the largest cytogenic study published to date sug-
gest the existence of a possible unique pathway of genetic
evolution of breast cancers, involving unbalanced
chromosome translocations, endoreduplication and further
chromosome losses (Dutrillaux et al., 1991). This was
achieved by analysing the proportion of rearranged
chromosomes against the modal number of chromosome
counts. Most importantly, it was consequently shown that
the loss of both oestrogen and progesterone receptors was
more frequent as the karyotypes became more complex
(Magdelenat et al., 1992). A similar pattern has been
confirmed for S-phase fraction (Remvikos et al., 1992) or
histopathological grade (Zafrani & Dutrillaux, unpublished
results). Although at present the data are insufficient to
discuss the chronology of the events, it can be hypothesised
that a set of biological parameters (including S-phase frac-
tion) correlate with the state of genetic evolution, a finding
that could explain their potential prognostic value.
Finally, it must be stressed that S-phase fractions of breast
cancer present the additional value of interaction with treat-
ment. We have previously suggested the existence of a rela-
tionship between S-phase fraction and response to neoad-
juvant chemotherapy (Remvikos et al., 1989). This has been
confirmed by different groups (Spyratos et al., 1992; O'Reilly
et al., 1992). One can speculate that different therapeutic
strategies could be developed, not only based on prognosis,
but also designed to achieve improved efficacy against
tumours with different proliferative characteristics, much in
the same way as it has been proposed that accelerated frac-
tionation radiotherapy should be used for fast growing
tumours (Peters et al., 1988).
In the light of these comments, the decision to publish or
not to publish the negative results of the study by Stanton et
al. appears to be a secondary point. Although it is claimed
that it counterbalances some other overoptimistic studies, its
contribution to our knowledge on breast cancer proliferation
and its prognostic value is quite limited.
Yours etc,
Y. Remvikos
Laboratoire de Radiopathologie
Institut Curie,
26, rue d'Ulm,
75231 Paris, France
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